Composed of distinguished medical scholars and practitioners from around the world, the Leeaf Scientific Board supervises our ongoing research efforts and ensures the required level of expertise. Today, we are proud to introduce Prof. Dr. Gabor L. Kovacs, M.D., chairman of our Leeaf scientific board.

Dr. Kovacs is a member of the Hungarian Academy of Sciences and the founding president of the Szentagothai Research Center at the University of Pecs (HU). He is the scientific leader of the National Laboratory on Human Reproduction and has released numerous scientific publications, with areas of research including laboratory medicine, endocrinology, clinical medicine as well as general health sciences. Dr. Kovacs's current scientific interest lies in the innovative diagnostic biomarker research of human reproduction.

"At this point, my own scientific interest and those of Leeaf have met each other to positively impact the conception by delivering innovative fertility diagnostics and treatment recommendations to doctors and patients," says Dr. Kovasc.

Starting January 2023, Leeaf is conducting a prospective, multi-centric, international research study with richer than ever four-dimensional patient data (medical, lifestyle, environmental, and genetic) to allow scientists to look deeper into factors that may influence the outcomes of controlled ovarian stimulation.

Building on several previously completed scientific studies on artificial intelligence in IVF, this observational study collects data to develop and fine-tune Leeaf’s algorithms, which will support IVF specialists in treatment selection through the Leeaf Physician Portal. The subsequent randomised control trial (RCT) will prove the efficacy of the proposed algorithms and models. First observations will be available in March, with first conclusions expected by the end of June.

To date, Leeaf has assembled an international scientific board consisting of high-profile IVF experts across the Czech Republic, Hungary, Spain, the United Kingdom, and the United States to oversee the strategic direction of Leeaf's research efforts.

The study is conducted under the supervision of Jan Choma, Co-Founder and Co-CEO of Leeaf, who oversees research activities and coordinates the medical and scientific boards.

Reach out to Jan to join our study at [email protected]

Leeaf has been recognized as one of the Top "20 Most innovative Companies to Watch" by Business Worldwide Magazine, a leading source of business and dealmaker intelligence.

It is an honor to receive such public recognition for our data-driven fertility health platform and it is a great motivation for our team of developers and product designers who work incredibly hard every day to refine our efficient decision supportive tool.

Leeaf has been featured in several media outlets:
TechDog - http://bit.ly/3havhlC
Yahoo Finance - https://bit.ly/3FBgWYI
Seeking Alpha - https://bit.ly/3Hif8oI

We are greatly honoured that Leeaf was recognised as one of the Top 200 companies to watch during the 2022 Websummit in Lisbon, Portugal.

Among 2 296 attending start-ups we were recognized as one of the most aspiring companies to watch and invited to an exclusive networking event, the Gathering, to meet with with like-minded tech enthusiasts and entrepreneurs.
To us, this recognition confirms that our hard work and the every-day effort that we put into developing our solution pays off and that we are headed into the right direction.

It has been an honor to receive such recognition for our data-driven fertility health platform and we will continue building our efficient decision supportive tool to guide patients globally on their fertility journey and support physicians in treatment selection.

In the meantime, we hope to meet many of you at the Fertility Conference - Reproduction in an aging world in Belfast, UK in January 11th-14th 2023.

Follow Leeaf on social media and subscribe to our newsletter to stay in touch and informed!